Clinical Trial Search

Primary: Change in HAM-A Total Score — -12.9; -15.7; -12.5 Units on a Scale — p=0.6540

Primary: Hamilton Anxiety Rating Scale (HAM-A) — 25.9; 23.8; 20.9; 19.4 units on a scale — p=.17

Primary: High End State Function — 56.52; 43.48; 56.52; 47.62 % people meeting high endstate status

Primary: Generalized Anxiety Disorder (GAD) Remission as Measured by Anxiety Disorders Interview Schedule-Adult Version (ADIS-IV) Severity Ratings — 4; 6; 7 Participants

Primary: Change From Baseline in the HAM-A Total Score at Week 8 — -9.28; -9.35 score on a scale — p=0.917

Primary: Penn State Worry Questionnaire - Measure of Symptom Change — 42.1; 55.8 score on a scale — p=<0.05

Primary: Signal Change in Brain Activity in the Amygdala When Viewing Emotional Faces — .1489; .1074; .0119; .1404 Percent signal change in brain acitivity

Primary: Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score at Endpoint — 12.76; 13.56; -6.38; -5.29 Units on a scale — p=0.006

Primary: Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Visit 7 (Day 42) — -9.01; -8.93 Score on scale

Primary: Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg — 10.638; 10.008…

Primary: Least Square Mean Change From Randomization to Week 8 in Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.74; -9.61 units on scale

Primary: Change in Hamilton Anxiety Rating Scale Score — -6.4 units on a scale

Primary: Proportion of Participants With Treatment Response — 0.54; 0.71; 0.33 Proportion of participants — p=.03

Primary: Hamilton Anxiety Rating Scale — 18; 15; 14; 8 participants — p=<.001

Primary: Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.1; -10.4; -10.8; -9.5 Units on scale

Primary: Clinician's Severity Rating (CSR) Scale of Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) — 5.5; 3.14; 2.43 units on a scale

Primary: Changes From Baseline in Penn State Worry Questionnaire (PSWQ-A) at Week 13 — -9.44; -5.37 units on a scale

Primary: Active Symptoms of Generalized Anxiety Disorder — 13.65; 16.27 units on a scale

Primary: Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed — 25.5; 25.6; 25.5; 25.8 score on a scale

Primary: Change in the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) at Post-treatment and 3-month Follow-up. — 25.31; 20.75; 12.10; 14.38 units on a…

Primary: Effect of Escitalopram After 8 Weeks of Treatment in Patients With GAD Using the Hamilton Anxiety Scale (HAMA) — 13.1 scores on a scale

Primary: Liebowitz Social Anxiety Scale (LSAS) — 68.1; 74.5; 60.0; 46.1 units on a scale

Primary: Change From Baseline to Week 8 in the Total Score on the Hamilton Anxiety Scale (HAM-A), as Assessed by the Site-trained Rater — -10.0; -9.3; -9.5 Units on a scale

Primary: Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 — 25.8; 24.9; 24.4; -7.7 units on a scale

Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.9; -11.1; -11.5; -10.9 Units on scale

Primary: Clinician Global Improvement Scale (CGI-21) — 7.8; 3.4 units on a scale

Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 14.7; 11.3 Score on Scale — p=0.0048

Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 13.1; 12.0; 11.2 Score on scale — p=0.0830

Primary: Feasibility of Participant Recruitment and Intervention Delivery — 8; 8 months

Primary: Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-responders — 17; 11; 10 participants